IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

CAPRARO ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/013179

FILED: 19 NOVEMBER 2004

U.S. APPLICATION NO: 10/579,876

35 USC §371 DATE: 02 FEBRUARY 2007

FOR: 1H-IMIDAZO(4,5-C)QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed May 18, 2006. Since Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, no fees are believed to be required under 37 C.F.R. §1.97(b)(3). If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898

Date: June 15, 2007

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 33511-US-PCT
APPLICATION NO. 10/579,876
APPLICANT CAPRARO ET AL.
FILING DATE FEBRUARY 2, 2007
Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AM						☐	☐
	AN						☐	☐
	AO						☐	☐
	AP						☐	☐
	AQ						☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Cantley et al., "New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/Akt pathway. Proceeding National Academic USA; 96:4240-4245
	AS	Vazquez et al., "The PTEN suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochimica et Biochimica et Biophysica Acta; 1470:M21-M35 (2000)
	AT	Simpson et al., "PTEN: Life as a tumor suppressor" Experimental Cell Research; 264:29-41 (2001)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 33511-US-PCT
APPLICATION NO. 10/579,876
APPLICANT CAPRARO ET AL.
FILING DATE FEBRUARY 2, 2007
Group

EXAMINER INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Li et al., "PTEN, "A putative protein tyrosine phosphatasegene mutated in human brain, breast and prostate cancers; Vol. 275:1943-1947 (1997)
	DB	Steck et al., "Identification of a candidate tumour suppressor gene MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics; Vol. 15:356-362 (1997)
	DC	Nagase et al., "Deletion mapping on chromosome 10q25-q26 in human endometrial cancer, British Journal of Cancer; Vol. 74:1979-1983 (1996)
	DD	Peiffer et al., "Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers," Cancer Research; Vol. 55:1922-1926 (1995)
	DE	Gray et al., "Loss of the chromosomal region 10q23-25 in prostate cancer," Cancer Research, Vol. 55(21):4800-3 (1995)
	DF	Ittmann M., "Allelic loss on chromosome 10 in prostate Adenocarcinoma Cancer Research; Vol. 56:2143-2147 (1996)
	DG	Perren et al., "Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast," Am J Pathol, Vol. 155(4):1253-1260 (1999)
	DH	Roberston et al., "the chromosome 10 monosomy common in human melanomas results from loss of two separate tumor suppressor loci, Cancer Res., Vol. 59(15):3596-3601 (1999)
	DI	Cairns et al., "Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene; Vol. 16:3215-3218 (1998)
	DJ	Gronback et al., "Alterations of the MMAC1/PTEN gene in lymphoid malignancies, Blood, Vol. 91:4388-4390 (1998)
	DK	Kim et al., "Alterations of PTEN/MMAC1, a candidate tumour suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines, Oncogene, Vol. 16:89-93 (1998)
	DL	Haas-Kogan et al., "Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor supporessor PTEN/MMAC1. Current Biology; Vol. 8:195-1198
	DM	Whang et al., "Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression, Proceeding National Academic Science USA; Vol. 95:5246-5250 (1998)
	DN	Wu et al., "The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phospholnositide 3-kinase/Akt pathway. Proceeding National Academic Science USA; Vol. 95:15587-15591 (1998)

EXAMINER **DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 33511-US-PCT
APPLICATION NO. 10/579,876
APPLICANT CAPRARO ET AL.
FILING DATE FEBRUARY 2, 2007
Group

EXAMINER INITIAL		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)
	DA	Yi-Hong Zhou et al., Clinical Cancer Research, Vol. 9:3369-3375 (2003)
	DB	Pullen et al., Sci, Vol. 279:707-710 (1998)
	DC	Santoro et al., Ann. N.Y. Acad. Sci., Vol. 963:116-121 (2002)
	DD	
	DE	
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.